Claims

1. Use of a composition comprising an enzymatic cocktail comprising Dispersin B and cellulase and DNase and at least one microbicidal molecule chosen from the group composed of fluoroquinolones, glycopeptides, lipoglycopeptides, fusidic acid, penicillins, cephalosporins, carbapenems, monobactams, polymyxins, beta-lactams, macrolides, lincosamides, oxazolidinones, amphenicols, tetracyclines, aminoglycosides, rifamycins, nitrofurans, sulphonamides, nitroimidazoles antifungals, N-acetylcysteine, antimicrobial peptides, and mixtures thereof in the manufacture of a medicament in the curative treatment of infections in the tissues, bones and cartilage and/or the internal mucosa of the body at an implantation site, said infections being post-implantation infections of mammalian bodies, wherein the said enzymatic cocktail and the said microbiocidal molecule are to be administered as combination products, for simultaneous use, separated use or use staggered over time.
2. Use of the composition according to claim 1, wherein said enzymatic cocktail further comprises one or several enzymes chosen from the group composed of lipases.
3. Use of the composition according to claim 1 or 2, wherein each enzyme is present in a concentration ranging between 0.01 and 1000mg/L.
4. Use of the composition according to any one of claims 1 to 3, wherein said at least one microbiocidal molecule chosen from the group composed of fluoroquinolones, glycopeptides, lipoglycopeptides, fusidic acid, penicillins, cephalosporins, carbapenems, monobactams, polymyxins, beta-lactams, macrolides, lincosamides, oxazolidinones, amphenicols, tetracyclines, aminoglycosides, rifamycins, nitrofurans, sulphonamides, nitroimidazoles antifungals, N-acetylcysteine, antimicrobial peptides, and mixtures thereof is present in a concentration ranging between 0.01 and 1000mg/L.
5. Use of the composition according to any one of claims 1 to 4, said composition being in the form of a sterile aqueous solution, which may be diluted or not in water for injectable preparation or in the form of a soluble powder, preferably in the form of a lyophilisate, or in the form of a gel.
6. Use of the composition according to any one of claims 1 to 5, said post-implantation infections of mammalian bodies, being post-implantation infections

of Staphylococcus aureus bacteria, Staphylococcus epidermis bacteria, Escherichia coli bacteria, Enterococcus faecalis bacteria, Klebsiella pneumoniae bacteria and Pseudomonas aeruginosa bacteria.

7. Use of the composition according to any one of claims 1 to 6, said post-implantation infections of mammalian bodies, being infections localised at an implantation site of an implantable medical device.
8. Use of the composition according to any one of claims 1 to 7, said composition to kill at least 1 Log10, of the microorganisms responsible for post-implantation infections of mammalian bodies, in particular in the human body.